Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/11/2861372/0/en/Algernon-Pharmaceuticals-CEO-Christopher-J-Moreau-to-Be-Featured-on-Radius-Research-s-Pitch-Deep-Dive-and-Q-A-Webinar-on-April-16th-2024.html
https://www.globenewswire.com/news-release/2024/04/01/2855067/0/en/Algernon-Pharmaceuticals-to-Move-Forward-with-Psychedelic-Drug-DMT-Stroke-Research-Program-as-its-Lead-Asset.html
https://www.globenewswire.com/news-release/2024/03/27/2853408/0/en/Algernon-Pharmaceuticals-Announces-Closing-of-the-Acquisition-of-its-Chronic-Cough-Research-Program-by-U-S-Based-Seyltx-for-USD-2M-and-a-20-Equity-Position.html
https://www.globenewswire.com/news-release/2024/01/31/2820948/0/en/Algernon-Pharmaceuticals-Receives-Notice-of-Intention-to-Grant-from-Chinese-Patent-Office-for-Repirinast-to-Treat-CKD.html
https://www.globenewswire.com//news-release/2024/01/11/2807778/0/en/Algernon-Pharmaceuticals-Announces-Notice-of-Allowance-for-Ifenprodil-Patent-in-Japan-for-Idiopathic-Pulmonary-Fibrosis.html
https://www.globenewswire.com//news-release/2023/12/27/2801516/0/en/Algernon-Pharmaceuticals-Announces-Closing-of-Private-Placement.html
https://www.globenewswire.com//news-release/2023/12/27/2801312/0/en/Algernon-Pharmaceuticals-Announces-Increase-to-Private-Placement.html
https://www.globenewswire.com//news-release/2023/12/13/2795182/0/en/Algernon-Pharmaceuticals-Announces-Private-Placement.html
https://www.globenewswire.com//news-release/2023/11/30/2788453/0/en/Algernon-Pharmaceuticals-Receives-Notice-of-Intention-to-Grant-from-Chinese-Patent-Office-for-Repirinast-to-Treat-NASH-and-NAFLD.html
https://www.globenewswire.com//news-release/2023/11/22/2784687/0/en/Algernon-Pharmaceuticals-Announces-LOI-for-the-Acquisition-of-its-Chronic-Cough-Research-Program-by-U-S-Based-Seyltx-for-USD-2M-and-a-20-Equity-Position.html